DORZOLAMIDE-TIMOLOL SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE); TIMOLOL (TIMOLOL MALEATE)

Pieejams no:

ALCON CANADA INC

ATĶ kods:

S01ED51

SNN (starptautisko nepatentēto nosaukumu):

TIMOLOL, COMBINATIONS

Deva:

2.0%; 0.5%

Zāļu forma:

SOLUTION

Kompozīcija:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 2.0%; TIMOLOL (TIMOLOL MALEATE) 0.5%

Ievadīšanas:

OPHTHALMIC

Vienības iepakojumā:

5ML/10ML

Receptes veids:

Prescription

Ārstniecības joma:

BETA-ADRENERGIC AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0237301001; AHFS:

Autorizācija statuss:

CANCELLED PRE MARKET

Autorizācija datums:

2021-06-25

Produkta apraksts

_Product Monograph – _
_ _
_Page 1 of 28_
_ _
_DORZOLAMIDE-TIMOLOL _
_ _
PRODUCT MONOGRAPH
PR
DORZOLAMIDE-TIMOLOL
Dorzolamide (as Dorzolamide Hydrochloride USP) 2.0% and
Timolol (as Timolol Maleate USP) 0.5% w/v
Sterile Ophthalmic Solution
Elevated Intraocular Pressure Therapy
(Topical Carbonic Anhydrase Inhibitor and Topical Beta-Adrenergic
Blocking Agent)
Alcon Canada Inc.
2665 Meadowpine Blvd.
Mississauga, ON
L5N 8C7
Date of Preparation:
October 1, 2010
SUBMISSION CONTROL NO: 131041
_Product Monograph – _
_ _
_Page 2 of 28_
_ _
_DORZOLAMIDE-TIMOLOL _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..................................................... 3
SUMMARY PRODUCT
INFORMATION.........................................................................
3
INDICATIONS AND CLINICAL
USE...............................................................................
3
CONTRAINDICATIONS
.....................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................
4
ADVERSE
REACTIONS......................................................................................................
7
DRUG
INTERACTIONS......................................................................................................
8
DOSAGE AND ADMINISTRATION
...............................................................................
10
OVERDOSAGE
...................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 11
STORAGE AND
STABILITY............................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 14
PART II: SCIENTIFIC INFORMATION
...........................................................................
15
PHARMACEUTICAL
INFORMATIO